Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Camber Capital Surges Stake In Sequenom Inc. (SQNM) To Over 5%

Camber Capital Management, managed by Stephen Dubois, is bullish on Sequenom Inc. (NASDAQ:SQNM). In a new filing with the Securities and Exchange Commission, Camber Capital disclosed a 5.41% passive stake in the company, containing 6.30 million shares, up from 2.91 million shares held previously.

Sequenom, Inc. (NASDAQ:SQNM)

Sequenom Inc. (NASDAQ:SQNM) is a life sciences company engaged in improving healthcare through revolutionary genomic and genetic analysis solutions. The company has a market cap of $422.5 million. At the end of last month, the company said it completed the sale of its Bioscience business to Agena Bioscience, a portfolio company of Telegraph Hill Partners. Under the agreement, Sequenom Inc. (NASDAQ:SQNM) will receive $31.8 million, subject to certain adjustments, and may also receive up to $4 million in contingent consideration upon the achievement of certain regulatory and sales milestones, according to a statement.

For the first quarter of 2014, the company posted a net loss of $15.7 million, or $0.13 per share, compared to net loss of $29.4 million, or $0.26 per share, for the same period of 2013. Adjusted net loss for the first quarter was $14.7 million, or $0.13 per share. The company reported revenue of $46.3 million for the first quarter, representing an increase of 20% compared to revenue of $38.5 million for the first quarter of 2013. Revenues from diagnostic services was up 27%, compared to the first quarter of 2013, and 13% on a sequential basis over the fourth quarter of 2013.

On Monday, the company’s stock rose 0.97% to $3.62. It has a 52 week high of $4.90 and a 52 week low of $1.65. The consensus average target price is $4.63 on the stock, while the consensus average recommendation is ‘overweight.’

In addition to Camber Capital, other significant shareholders of Sequenom Inc. (NASDAQ:SQNM) include William Leland Edwards‘ Palo Alto Investors and Youlia Miteva’s Proxima Capital Management, owning 9.79 million shares and 2.21 million shares, respectively.

Disclosure: none

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...